Is there life for CETP inhibitors after the death of torcetrapib?
In the beginning of this year, I wrote two articles concerning torcetrapib, the $800 million failure of Pfizer to develop a new type of cholesterol medication. This novel medication called a CETP (cholesterol ester transfer protein) inhibitor is able to markedly raise HDL, but unfortunately was found to increase the risk of death. The increased... Read more
